Symptomatic Epstein-Barr virus reactivation in a patient with acute myeloid leukaemia and treatment with the monoclonal anti-CD20 antibody rituximab.
In a patient with acute myeloid leukaemia, treated with several courses of chemotherapy including a fludarabine-containing regimen, severe symptoms due to Epstein-Barr virus reactivation occurred but could be successfully treated with the monoclonal anti-CD20 antibody rituximab. Depletion of viral host cells may be effective in treatment of symptoms due to Epstein-Barr virus reactivation.